miR-127-5p negatively regulates enterovirus 71 replication by directly targeting SCARB2

Chunhong Feng1,2, Yuxuan Fu1, Deyan Chen1, Huanru Wang1, Airong Su1, Li Zhang1, Liang Chang1, Nan Zheng1,3,4 and Zhiwei Wu1,3,4

1 Center for Public Health Research, Medical School, Nanjing University, China
2 School of life sciences, Nanjing University, China
3 State Key Lab of Analytical Chemistry for Life Science, Nanjing University, China
4 Medical School and Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, China

Keywords
Enterovirus 71; miR-127-5p; SCARB2; viral replication

Correspondence
Z. Wu, Center for Public Health Research, School of Medicine, Nanjing University, 22# Hankou Road, Nanjing, Jiangsu Province 210093, China
Fax: +86 (25) 8359-6023
Tel: +86 (25) 8368-6092
E-mail: wzhw@nju.edu.cn

(Received 9 October 2016, revised 27 December 2016, accepted 16 January 2017)

doi:10.1002/2211-5463.12197

Enterovirus 71 (EV71) is the major causative agent of hand-foot-and-mouth disease in young children and can cause severe cerebral and pulmonary complications and even fatality. This study aimed at elucidating whether and how EV71 infection is regulated by a cellular microRNA, miR-127-5p. We found that miR-127-5p can downregulate the expression of SCARB2, a main receptor of EV71, by targeting two potential sites in its 3’ UTR region and inhibit EV71 infection. Meanwhile, miR-127-5p expression was upregulated during EV71 infection. Notably, transfecting cells with miR-127-5p mimics led to a significant decrease in viral replication, while inhibition of endogenous miR-127-5p facilitated viral replication. Furthermore, our evidence showed that miR-127-5p did not affect postentry viral replication. Taken together, these results indicated that miR-127-5p inhibited EV71 replication by targeting the SCARB2 mRNA.

MicroRNAs (miRNAs) are a class of highly conserved noncoding RNA oligonucleotides of 21–22 nucleotides that are found in animals, plants, and viruses [1–3]. These small RNAs primarily regulate the expression of specific genes by binding to complementary sequences at target mRNAs to modulate their translation or stability. There are hundreds of miRNA-encoding genes in humans, which regulate protein-encoding genes [4,5]. Growing evidence has demonstrated that miRNAs regulate a wide range of biological processes, including development, differentiation, cell proliferation, apoptosis, and immune responses [1,4].

Enterovirus 71 (EV71), a positive, single-stranded RNA virus belonging to the family of Picornaviridae [6,7], was first isolated from patients with neurological diseases, including fatal encephalitis and aseptic meningitis, in California in 1969 [8]. Later studies suggested that EV71 is associated with hand-foot-and-mouth disease (HFMD) in young children and infants [9]. In recent years, epidemic or sporadic outbreaks of neurovirulent EV71 infections have been reported in Southeast or East Asia, including Taiwan, Malaysia, Singapore, Japan, and China [10–12]. EV71 infection has become a public health challenge. Although a vaccine has recently been approved in China, its clinical benefits remain to be seen.

Recently, miRNAs have been noted to be key effector molecules in the complex interaction network between virus and host [3,13], either by targeting cellular factors used for virus replication [14,15] or by directly targeting viral miRNAs [16–18]. Plus-strand RNA virus replication requires the recruitment of...
specific host factors at various steps in the process. These host factors help viral genomic replication, viral protein synthesis, and defense against host immune response [19].

Viral entry into host cells during infection is initiated by receptor-mediated endocytosis involving specific cellular surface components [20]. In the previous studies, a number of molecules have been identified to be functional receptors for EV71, including scavenger receptor class B, member 2 (SCARB2) [21], and P-selectin glycoprotein ligand-1 (PSGL-1) [22]. SCARB2 is expressed ubiquitously on the membrane of various cells and tissues [21]. As a receptor for all strains of EV71, SCARB2 is capable of mediating viral binding, internalization, and uncoating, and is shown to play a crucial role in the early steps of EV71 infection [23,24]. However, PSGL-1 expressed on leukocytes has an important role in the tethering and rolling of leukocytes during recruitment of cells from blood vessels to the sites of acute inflammation upon stimulation by infection, but its exact role in nonleukocytes remains unclear [25–27]. A correlation between viral infection and SCARB2 expression appears to be more significant than for PSGL-1 expression [28]. Reports have shown that miR-127-5p targets SCARB2 3′ UTR and leads to a significant reduction in both mRNA and protein levels of SCARB2 [29]. Studies on other viruses have shown that miRNAs can prevent the virus entry by targeting the 3′ untranslated region (UTR) of receptor mRNA to inhibit viral infection. For example, recent studies by Mekky et al. [30] revealed that miR-194 hinders HCV entry through targeting CD81 receptor. miR-320a and miR-140 inhibit mink enteritis virus infection by repressing its receptor, feline transferrin receptor [31]. miRNAs mediate gene knockdown of cell surface receptors to significantly reduce FMDV infection in cell culture and transgenic suckling mice [32]. miR-23b blocks infections of RV1B through downregulation of its receptor, VLDLR [33]. However, although SCARB2 siRNA can significantly reduce EV71 replication [34], whether and how SCARB2 is regulated by cellular miRNAs during EV71 infection are unknown. In the current study, we examined the role of cellular miR-127-5p on EV71 infection and found that miR-127-5p negatively regulates EV71 replication by suppressing the expression of the EV71 cellular receptor SCARB2. Our results will provide new insights into the inhibitory roles of cellular miR-127-5p in EV71 infection and useful information for the identification of novel intervention targets to reduce EV71 infection and pathogenesis.

### Materials and methods

#### Cell culture

Vero (derived from African green monkey kidney cells), HeLa (a human epithelial carcinoma cell line), HepG2 (a human hepatoma cell line), 293T (a transformed embryonic kidney cell line expressing SV40 large T antigen), and L929 (mouse fibroblast cells) were grown in Dulbecco’s modified Eagle’s medium (DMEM; HyClone, Logan, UT, USA) supplemented with 10% or 2% FBS (Gibco, Carlsbad, CA, USA) at 37 °C in a humidified 5% CO2 incubator.

#### Synthetic oligonucleotides and transfection

Negative control mimics, miR-127-5p mimics, negative control inhibitor, and miR-127-5p inhibitor were purchased from RiboBio (Guangzhou, China). For transfection, the cells were plated in six-well plates, grown to 30% confluence, and were transfected with synthetic oligonucleotides using Lipofectamine 3000 (Life Technologies, Carlsbad, CA, USA), according to the manufacturer’s instruction.

#### RNA isolation and quantitative real-time PCR

According to the manufacturer’s protocol, total RNA was prepared using Trizol reagent (Life Technologies). Reverse-transcribed cDNA was synthesized using the PrimeScript RT Reagent Kit (TaKaRa, Dalian, China). GAPDH mRNA was used as an endogenous control for the expression of SCARB2 and EV71 VP1 genomic RNA. The primers used were:

**SCARB2-F**: 5′-CCATAGAAAGCCATGCACCCA-3′, **SCARB2-R**: 5′-AGCGCCATGATGTAGGG-3′, **EV71VP1-F**: 5′-GCTCTATAGGAGATAGTGTGAGTAGGG-3′, **EV71 VP1-R**: 5′-GTGACTCCTACCCCTGCTGTT-3′, **GAPDH-F**: 5′-TGCAACCCACACTGTCATGAC-3′, **GAPDH-R**: 5′-GACATGGACTGTGGTCTAG-3′.

To determine the expression of miRNA in cells, U6 snRNA served as an internal control, and miR-127-5p quantitative real-time PCR (qRT-PCR) primers were purchased from RiboBio. Real-time PCR was performed using a standard protocol on an Applied Biosystems 7300 system using SYBR green PCR master mix (Life Technologies) according to the manufacturer’s instruction. All reactions were performed in triplicate and relative expression was analyzed using the ΔΔCt method.

#### Western blot and antibody reagent

Cells were collected and lysed using RIPA lysis buffer (Santa Cruz, CA, USA) on ice for 20 min and then centrifuged at 12 000 g for 10 min at 4 °C. Total protein...
concentrations were determined using the Bicinchoninic Acid (BCA) Protein Assay Kit (Pierce, Rockford, IL, USA). Proteins were analyzed by SDS/PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA). Nonspecific antibody binding was blocked by Odyssey Blocking buffer (LI-COR Biosciences, Lincoln, NE, USA), and the membranes were incubated with primary antibodies specific for SCARB2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). EV71 VP1 (Abcam, Cambridge, UK), or GAPDH (Santa Cruz Biotechnology) for 4 h at room temperature (RT). After five washes with PBS-0.1% Tween-20 (PBS-T buffer), the membranes were incubated with IRDye 800 goat anti-mouse IgG or IRDye 680 donkey anti-rabbit IgG (LI-COR Biosciences) at 1 : 10 000 dilution for 1 h and visualized using Li-COR Odyssey Infrared Imager (LI-COR Biosciences). Bands were quantified by densitometric analysis using ODYSSEY software.

**Virus titer**

Enterovirus 71 Fuyang0805 strain was propagated on Vero cells. Vero cells were grown in 96-well plates, 24 h before virus infection. EV71 was serially diluted with DMEM supplemented with 2% FBS from 10^3 to 10^{12}-fold, and a dilution of EV71 was added to triplicate wells. The plates were then incubated at 37 °C with 5% CO2. The cytopathic effect (CPE) was recorded under the microscope after 3 days. Virus titers were calculated as the 50% tissue culture infectious dose (TCID_{50}) using the Reed–Münnich method.

**Plasmid constructs**

The wild-type pmirGLO-SCARB2 3’ UTR reporter plasmid was constructed by inserting the 3’ UTR (nucleotides 270–1240) of SCARB2 into the pmirGLO luciferase vector between the XhoI and XbaI sites. The SCARB2 3’ UTR was amplified from cDNA using forward primer F (5’-CC GCTCGAGTTGTTGGGTGCTGGTAGCTC-3’) and the reverse primer R (5’-GCTCTAGAGGTGTCTCTGCTT CTGGTCC-3’). The mutant pmirGLO-SCARB2 3’ UTR construct was generated by inducing a point mutation using the overlap extension PCR method.

**Luciferase assay**

For the luciferase assay, 293T cells were plated at a density of 1 x 10^4 cells per well in 24-well plates and luciferase reporter plasmids and pLR-Tk (Promega, Madison, WI, USA) were cotransfected into 293T cells using Lipofectamine 3000 (Life Technologies). After 48 h of incubation, the cells were harvested, washed once with PBS, and lysed with Passive lysis buffer (Promega). Supernatants were collected after 15 min, and centrifuged at 12 000 g for 30 s.

The luciferase activities were measured using a dual-luciferase reporter system (Promega).

**Immunofluorescence assay**

Cells were seeded on glass coverslips, and were infected with EV71 at the indicated time, followed by fixation with 4% paraformaldehyde for 15 min at room temperature. After being washed twice with PBS, the cells were treated with specific primary antibodies against the proteins. The respective secondary antibody was Alexa Fluor 594-labeled donkey anti-mouse IgG (Molecular Probes, Life technologies) diluted at 1 : 1000. Images were acquired with an Olympus Fluoview FV10i laser scanning confocal microscope (Tokyo, Japan).

**Flow cytometry**

The cells were dispersed with PBS containing 0.02% EDTA, harvested, and fixed in 4% paraformaldehyde. After three washes with PBS, cells were incubated with the SCARB2-specific antibody (diluted 1 : 100, Santa Cruz, CA, USA) in PBS containing 1% BSA at room temperature for 1 h, followed by incubation with the Alexa Fluor 488-labeled goat anti-mouse IgG (Molecular Probes, Life technologies) at 1 : 1000 for 30 min. SCARB2 protein on the cell surface was analyzed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) using a FLOWJO software (TreeStar Software, San Carlos, CA, USA).

**Statistical analysis**

The statistical analyses were performed using PRISM 5.0 software (GraphPad Software, La Jolla, CA, USA). Differences between experimental groups were statistically evaluated using Student’s t-test. P-value of <0.05 was considered statistically significant (*P < 0.05, **P < 0.01, and ***P < 0.001). All the results are presented as means ± SD of at least three independent experiments.

**Results**

**miR-127-5p inhibits SCARB2 expression by targeting its 3’ UTR**

Recently, Siebert, et al. [29] reported that miR-127-5p targeted SCARB2 3’ UTR and reduced the protein expression of SCARB2. As a cellular receptor, SCARB2 can facilitate efficient EV71 infection [35]. Firstly, we observed the differential surface expression of SCARB2 on HeLa and HepG2 cells (Fig. 1A), and showed that this differential expression of SCARB2 appears to impact on the
Suppression of EV71 replication by miR-127-5p
C. Feng et al.

Fig. 1. miR-127-5p inhibits SCARB2 expression by targeting its 3’ UTR. (A) HeLa and HepG2 cells were stained with the anti-SCARB2 antibody (solid lines) or normal mouse IgG (dotted lines), and then the surface SCARB2 expression was analyzed by flow cytometry. (B) Susceptibility of HeLa and HepG2 cells to EV71. CPE of HeLa and HepG2 cells infected with EV71. HeLa and HepG2 cells were infected with EV71 at an MOI of 0.1. At 48 h postinfection, these cells were imaged via light microscopy. Scale bar, 100 μm. (C) The cells were lysed and total RNA was extracted. Level of miR-127-5p was determined by quantitative real-time PCR analysis. (D and E) HeLa and HepG2 cells were transfected with miR-127-5p mimics or NC mimics (final concentration, 50 nM) for 48 h. The cells were lysed and total RNA was extracted. SCARB2 mRNA level was determined by quantitative real-time PCR analysis. (E) SCARB2 protein expression in HeLa and HepG2 cells was detected by western blot analysis. The numbers represent the relative density of the band in comparison to the corresponding control normalized to GAPDH. Value of NC mimics treatment is set at 1.00 (100%). (F and G) HeLa and HepG2 cells were transfected with miR-127-5p inhibitor or NC inhibitor (final concentration, 100 nM) for 48 h. SCARB2 mRNA level was determined by quantitative real-time PCR analysis. (G) SCARB2 protein level in HeLa and HepG2 cells was determined by western blot analysis. The numbers denote the relative density of the bands normalized to the control. (H) The illustration of SCARB2 wild-type or mutant 3’ UTRs containing the putative miR-127-5p-binding sites. (I) Luciferase reporters with SCARB2 3’ UTR wt, SCARB2 3’ UTR mut1, SCARB2 3’ UTR mut2, or SCARB2 3’ UTR mut1/2 were transfected into 293T cells together with miR-127-5p mimics or NC mimics. Forty-eight hours after transfection, the luciferase activity assays were carried out. Data are representative of at least three independent experiments, with each measurement performed in triplicate (mean ± SD of fold-change). *P < 0.05, **P < 0.01, ***P < 0.001.
susceptibility of HeLa and HepG2 cells to EV71 infection (Fig. 1B). We found that the progression of cytopathic effects in HepG2 cells was slower than that in HeLa cells, suggesting that the efficiency of EV71 infection was correlated with the level of cell surface SCARB2 expression (Fig. 1A,B). Additionally, we also found that HeLa cells expressed a relative lower level of miR-127-5p (Fig. 1C). We then investigated if miR-127-5p directly suppresses SCARB2 expression by transfecting miR-127-5p mimics into both HeLa and HepG2 cells, and then measuring the expression of both SCARB2 mRNA and the protein. We found that miR-127-5p mimics significantly reduced both the mRNA level (Fig. 1D) and protein expression of SCARB2 (Fig. 1E), consistent with the previous observations obtained from different cell lines [29]. Consistent with above observation, a miR-127-5p inhibitor significantly increased mRNA level (Fig. 1F) and protein expression of SCARB2 (Fig. 1G), as compared to the negative control. To further verify that the downregulation of SCARB2 expression is due to targeting by miR-127-5p, we performed a bioinformatic search using microRNA (http://www.microrna.org/) to identify putative binding site and identified two seed regions at the 3' UTR of SCARB2 (nucleotides 369–374 and 484–490) that may bind miR-127-5p. In order to demonstrate that the binding sites are specific, we constructed expression plasmids of SCARB2 wild-type/mutant 3' UTR containing the putative miR-127-5p-binding sites by cloning into the pmirGLO reporter vector. Mutant reporter constructs were generated with underlined nucleotides indicating the mutated sequences as shown in Fig. 1H. We cotransfected pmirGLO plasmid into 293T cells, along with miR-127-5p mimics or negative control mimics. The luciferase activity of SCARB2 3' UTR wt was significantly reduced in 293T cells treated with miR-127-5p mimics, whereas the SCARB2 3' UTR mut1 or SCARB2 3' UTR mut2 partly reversed the inhibition of luciferase activity by miR-127-5p mimics. Additionally, the luciferase activity in the cells transfected with the SCARB2 3' UTR mut1/2 vector was unaffected by the miR-127-5p mimics (Fig. 1I). This result was in agreement with a previous study showing that miR-127-5p had effect on the luciferasesla and HepG2 cells to EV71 infection (Fig. 1B). We found that the progression of cytopathic effects in HepG2 cells was slower than that in HeLa cells, suggesting that the efficiency of EV71 infection was correlated with the level of cell surface SCARB2 expression (Fig. 1A,B). Additionally, we also found that HeLa cells expressed a relative lower level of miR-127-5p (Fig. 1C). We then investigated if miR-127-5p directly suppresses SCARB2 expression by transfecting miR-127-5p mimics into both HeLa and HepG2 cells, and then measuring the expression of both SCARB2 mRNA and the protein. We found that miR-127-5p mimics significantly reduced both the mRNA level (Fig. 1D) and protein expression of SCARB2 (Fig. 1E), consistent with the previous observations obtained from different cell lines [29]. Consistent with above observation, a miR-127-5p inhibitor significantly increased mRNA level (Fig. 1F) and protein expression of SCARB2 (Fig. 1G), as compared to the negative control. To further verify that the downregulation of SCARB2 expression is due to targeting by miR-127-5p, we performed a bioinformatic search using microRNA (http://www.microrna.org/) to identify putative binding site and identified two seed regions at the 3' UTR of SCARB2 (nucleotides 369–374 and 484–490) that may bind miR-127-5p. In order to demonstrate that the binding sites are specific, we constructed expression plasmids of SCARB2 wild-type/mutant 3' UTR containing the putative miR-127-5p-binding sites by cloning into the pmirGLO reporter vector. Mutant reporter constructs were generated with underlined nucleotides indicating the mutated sequences as shown in Fig. 1H. We cotransfected pmirGLO plasmid into 293T cells, along with miR-127-5p mimics or negative control mimics. The luciferase activity of SCARB2 3' UTR wt was significantly reduced in 293T cells treated with miR-127-5p mimics, whereas the SCARB2 3' UTR mut1 or SCARB2 3' UTR mut2 partly reversed the inhibition of luciferase activity by miR-127-5p mimics. Additionally, the luciferase activity in the cells transfected with the SCARB2 3' UTR mut1/2 vector was unaffected by the miR-127-5p mimics (Fig. 1I). This result was in agreement with a previous study showing that miR-127-5p had effect on the luciferase
activity of pMIR-SCARB2 3′ UTR plasmid [29]. In summary, these data suggested that SCARB2 is a direct target of miR-127-5p and that its expression is modulated by miR-127-5p.

**EV71 infection upregulates miR-127-5p expression**

We investigated the expression of miR-127-5p in EV71-infected HeLa cells and found that cellular miR-127-5p expression at 12 h and 24 h postinfection was 2.8- and 3-fold higher, respectively, than that of the mock-infected HeLa cells (Fig. 2A). In EV71-infected HepG2 cells, the miR-127-5p expression at 12 h and 24 h was 2.4- and 2.5-fold higher than those of the mock-infected cells, respectively (Fig. 2B). Thus, these results demonstrated that EV71 infection upregulated miR-127-5p expression. To investigate whether upregulation of the miR-127-5p following EV71 infection could affect SCARB2 expression, quantitative real-time PCR and western blot were performed simultaneously to measure the SCARB2 expression in HeLa (Fig. 2C) and HepG2 cells (Fig. 2D) and, as expected, SCARB2 was slightly, but significantly, downregulated after EV71 infection.

**EV71 gene expression and replication are attenuated by miR-127-5p overexpression**

Earlier studies showed that SCARB2 siRNA treatment inhibited EV71 infection [34,36]. Similarly, our results have confirmed that miR-127-5p could suppress the SCARB2 expression (Fig. 1A,B). To further substantiate whether modulation of miR-127-5p expression would affect the surface expression of SCARB2, we transfected miR-127-5p mimics into both HeLa and HepG2 cells, and then analyzed by flow cytometry. The result suggested that upregulation of the miR-127-5p level led to a decrease in the surface expression of SCARB2 (Fig. 3A). Therefore, it is of interest to evaluate the effect of miR-127-5p on EV71 replication. For this purpose, miR-127-5p was overexpressed by miRNA mimics transfection and its effect on EV71 replication was assessed by measuring EV71 VP1 expression, the viral RNA level, viral titer, and percentage of infected cells. EV71 VP1 protein decreased in both HeLa and HepG2 cells overexpressing miR-127-5p, as compared to the negative control cells (Fig. 3B). The levels of SCARB2 mRNA (Fig. 3C) and EV71 RNA (Fig. 3D) in cells transfected with miR-127-5p mimics were significantly reduced. The EV71 titers at various times postinfection were also significantly suppressed by miR-127-5p overexpression, as compared to the control (Fig. 3E). Immunofluorescence staining of viral VP1 showed that the percentage of infected cells in cells overexpressing miR-127-5p was reduced by nearly 50%, as compared to the control, at 24 h postinfection (Fig. 3F). When HeLa cells were transfected with increasing concentrations of miR-127-5p mimics (10, 20, 40, and 50 nM), followed by EV71 infection, both SCARB2 mRNA and protein levels, as well as EV71 VP1 protein, were inhibited as a function of the dose of miR-127-5p mimics (Fig. 3G). These results showed that miR-127-5p overexpression downregulated SCARB2 expression and thus significantly reduced EV71 infection.
Suppression of EV71 replication by miR-127-5p
Suppression of endogenous miR-127-5p enhances EV71 replication

Next, we performed experiments to determine whether inhibition of endogenous miR-127-5p expression affects EV71 replication. A chemically synthesized oligonucleotide with sequence complementary to endogenous miR-127-5p was used to inhibit endogenous miR-127-5p expression. Such inhibitor oligonucleotides have been shown to sequester intracellular miRNAs and to inhibit their activity in the RNA interference pathway [37,38]. Interestingly, transfection of miR-127-5p inhibitor increased the surface SCARB2 expression (Fig. 4A). Moreover, HeLa and HepG2 cells transfected with the miR-127-5p inhibitor or NC inhibitor were subsequently infected with EV71, and EV71 VP1 expression, SCARB2 mRNA level, the viral RNA level, and viral titer were determined, respectively. The expression of EV71 VP1 protein (Fig. 4B) in HeLa and HepG2 cells was upregulated by the inhibition of endogenous miR-127-5p, as shown by western blot analysis. Consistently, the levels of SCARB2 mRNA (Fig. 4C) and EV71 RNA (Fig. 4D) were also higher in cells transfected with miR-127-5p inhibitor than in the negative control cells. We also found that the EV71 titer was significantly higher in cells treated with miR-127-5p inhibitor than that in untreated cells (Fig. 4E). In conclusion, these results demonstrated that inhibition of endogenous miR-127-5p led to enhancement of EV71 replication.

miR-127-5p does not influence intracellular replication of EV71

We postulate that mechanistically miR-127-5p downregulates cellular receptor SCARB2 and thus prevents the EV71 attachment to and entry into the cells. To further investigate the mechanism of miR-127-5p inhibition, we conducted a virus attachment analysis to determine if viral attachment is affected by the miR-127-5p-mediated down-modulation of SCARB2. The result showed that miR-127-5p significantly reduced the amount of VP1, as compared to the control cells (Fig. 5A). The above results suggested that miR-127-5p blocked entry of EV71 by inhibiting expression of the viral receptor SCARB2, resulting in the reduction of viral attachment.

Previous studies reported that viral genomic RNA is directly targeted by host miRNAs [39,40]. In order to rule out the possibility that EV71 genomic RNA is targeted by miR-127-5p in our research, studies were carried out to determine if EV71 genomic RNA contains potential target sequences for miR-127-5p. It had been demonstrated that hSCARB2, but not mScarb2, bound efficiently to EV71 [41]. Mouse L929 cells are not susceptible to EV71 infection and allow only inefficient EV71 infection, because they lack the cellular receptor [21,24,35]. In this study, we used L929 cells to investigate whether EV71 replication initiated by transfection of infectious viral genomic RNA is affected by miR-127-5p. High level of miR-127-5p was detected in miR-127-5p-transfected L929 cells, suggesting that the miR-127-5p was efficiently incorporated intracellularly (Fig. 5B). In the L929 cells transfected with EV71 genomic RNA, although increasing amounts of viral RNA were detected, no inhibitory effect of miR-127-5p was observed (Fig. 5C). In addition, EV71 VP1 expression showed no difference between the cells overexpressing miR-127-5p and the control cells (Fig. 5D). These results demonstrated that miR-127-5p suppressed infection of EV71 by downregulating the expression of its major cellular receptor, SCARB2, rather than impairing the intracellular viral replication.

Discussion

In recent years, morbidity and mortality due to EV71 infection have increased, whereas the underlying pathogenic mechanisms remain elusive, and intervention and therapeutic approaches are still limited. MicroRNAs serve as multifunctional regulators, and the significance of miRNAs in virus–host interactions is becoming evident. A growing number of studies show that host miRNAs can regulate viral replication by altering the expression of host genes required for viral response [30,42,43] or by directly targeting viral genomic RNAs [39,40,44]. To date, few studies have already explored the effects of miRNAs in EV71 infection; for example, miR-296-5p targets the EV71 genome to suppress viral replication [39]; miR-23b inhibits EV71 replication through downregulation of VP1 protein [45]; and our study showed that miR-30a inhibited EV71 replication by modulating EV71-induced autophagy [46]. In this report, we provided evidence on the effect of cellular miR-127-5p on SCARB2 expression and its inhibitory activity on EV71 infection. SCARB2 is considered to be a crucial EV71 receptor [23].

SCARB2 plays critical roles in viral attachment, entry, and uncoating, and it can promote EV71 infection [24]. Recently, a study demonstrated that human miR-127-5p significantly downregulated SCARB2 protein level by directly targeting SCARB2 mRNA [29]. As an important receptor for EV71, reduction in SCARB2 may prevent viral entry during primary infection. Thus, it is plausible to assume that miR-127-5p may impact EV71 infection by regulating SCARB2.
expression. In the current study, we first analyzed the influence of miR-127-5p mimics (Fig. 1E) or inhibitor (Fig. 1F) on the total cellular SCARB2 level by western blotting. Because SCARB2 is a lysosomal protein, and the majority of the protein is located in the lysosome and endosomes, these results will be difficult to

Fig. 4. Suppression of endogenous miR-127-5p enhances EV71 replication. (A) Flow cytometric analysis was used to assess the surface SCARB2 level of HeLa and HepG2 cells after 48 h transfection. The cells transfected with NC inhibitor (final concentration, 100 nM) were stained with the anti-SCARB2 antibody (solid lines), and transfected with miR-127-5p inhibitor (final concentration, 100 nM) were stained with anti-SCARB2 antibody (gray region), or the cells were stained with normal mouse IgG (dotted lines, the same result for the cells treating with NC inhibitor or miR-127-5p inhibitor). (B) HeLa and HepG2 cells were transfected with miR-127-5p inhibitor or NC inhibitor (final concentration, 100 nM) for 48 h and then infected with EV71 at an MOI of 2.0. The cells were harvested at 12 h and 24 h postinfection, and western blot analysis of the expression levels of EV71 VP1 was performed. The numbers below each band denote the relative density of the bands normalized to the control. (C–E) HeLa cells were transfected with miR-127-5p inhibitor or NC inhibitor for 48 h and then infected with EV71 (MOI = 2.0) at the indicated times. SCARB2 mRNA and EV71 VP1 mRNA levels were determined by quantitative real-time PCR analysis. (E) HeLa cells were transfected with miR-127-5p inhibitor or NC inhibitor for 48 h and then infected with EV71 (MOI = 0.5) at the indicated times. Culture supernatants were collected at the indicated times and virus was titrated. Virus titers were expressed as the log TCID50/mL. Data are representative of at least three independent experiments, with each measurement performed in triplicate (mean ± SD of fold-change). *P < 0.05, **P < 0.01, ***P < 0.001.
accurately reflect the change of surface SCARB2. Therefore, we performed the flow cytometric analysis of the cell surface SCARB2 expression, and the data indicated that overexpression of miR-127-5p significantly inhibited the surface SCARB2 expression (Fig. 3A), while inhibition of endogenous miR-127-5p significantly elevated the surface SCARB2 (Fig. 4A). Consistently, overexpression of miR-127-5p or inhibition of endogenous miRNA-127-5p resulted in repressed (Fig. 3B) or enhanced (Fig. 4B) production of EV71, respectively. Results from dual-luciferase assay validated that miR-127-5p targeted SCARB2 and thus inhibited protein translation of SCARB2. Studies with SCARB2 mutants and the inability of miR-127-5p in inhibition of EV71 replication in L929 cells (Fig. 5B–D) suggested that this miR-127-5p-mediated downregulation of SCARB2 was specific and miR-127-5p did not target at intracellular or viral sequences.

As miR-127-5p-mediated downregulation of SCARB2 likely impact only on the uninfected cells for their susceptibility to EV71 infection, it is likely that reduced infection is mainly resulted from decreased viral attachment to the cells with miR-127-5p-mediated SCARB2 downregulation. Our evidence that VP1 was reduced by more than 50% in cells overexpressing miR-127-5p and infected with EV71 for 1 h at 4 °C illustrated that the downregulated SCARB2 led to the reduced viral attachment. Downregulation of SCARB2 by miR-127-5p may be of significance for host defense to the EV71 as the binding of virus to the host cell is the initial step for viral entry; therefore, transient downregulation of cell surface molecules may be an effective strategy to block and reduce viral transmission. As several reports have shown [47–49], siRNAs can inhibit viral infection through various different mechanisms and can be used to control virus diseases in vivo.

Overall, we identified miR-127-5p as a novel EV71 entry inhibitor through targeting SCARB2 expression. To our knowledge this is the first study describing the role of microRNAs in regulating SCARB2 expression during EV71 infection. Endogenous miRNAs may possess advantages over siRNAs on safety and fewer side effects. The current study provides a new perspective for miRNA-mediated antiviral effects and contributes to the better understanding of host–virus interaction mechanisms.

**Acknowledgements**

This work was supported by The National Key Research and Development Program of China.

---

**Fig. 5.** miR-127-5p does not influence intracellular replication of EV71. (A) HeLa cells were transfected with miR-127-5p mimics or NC mimics (final concentration, 50 nM) for 48 h and the cells were infected by EV71 at an MOI of 10 in PBS containing 0.05% EDTA for 1 h at 4 °C. The cells were washed, lysed and EV71 VP1 protein level was determined by western blot and normalized to GAPDH. The numbers denote the relative density of the bands normalized to the control. (B–D) L929 cells were cotransfected with EV71 genomic RNA and miR-127-5p or NC mimics for 12 h and 24 h. Levels of miR-127-5p (B) and EV71 RNA (C) were determined by quantitative real-time PCR analysis. (D) EV71 VP1 level was determined by western blot and normalized to GAPDH. The numbers denote the relative density of the bands normalized to the control. Data are representative of at least three independent experiments, with each measurement performed in triplicate (mean ± SD of fold-change). ***P < 0.001.
(2016YFC1201000), the Major Research and Development Project from the Ministry of Health of China (2016ZX10001005003), and Nature Science Foundation of Jiangsu Province (BK20130591).

Author contributions
ZW conceived and supervised the study. CF designed and performed experiments. YF and DC provided new reagents and analyzed data. HW, AS, and NZ interpreted the data. LZ and LC provided new reagents. CF wrote the manuscript. ZW made manuscript revisions.

References
1 Moazed D (2009) Small RNAs in transcriptional gene silencing and genome defence. Nature 457, 413–420.
2 Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C et al. (2004) Identification of virus-encoded microRNAs. Science 304, 734–736.
3 Skalsky RL and Cullen BR (2010) Viruses, microRNAs, and host interactions. Annu Rev Microbiol 64, 123–141.
4 Ghildiyal M and Zamore PD (2009) Small silencing RNAs: an expanding universe. Nat Rev Genet 10, 94–108.
5 Jackson RJ and Standart N (2007) How do microRNAs regulate gene expression? Sci STKE 2007, re1.
6 AbuBakar S, Chee HY, Al-Kobaisi MF, Xiaoshan J, Chua KB and Lam SK (1999) Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res 61, 1–9.
7 Ashraf U, Zhu B, Ye J, Wan S, Nie Y, Chen Z, Cui M, Wang C, Duan X, Zhang H et al. (2016) MicroRNA-19b-3p modulates Japanese encephalitis virus-mediated inflammation via targeting RNF11. J Virol 90, 4780–4795.
8 Schmidt NJ, Lennette EH and Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129, 304–309.
9 Hagiwara A, Tagaya I and Yoneyama T (1978) Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology 9, 60–63.
10 Ahmad K (2000) Hand, foot, and mouth disease outbreak reported in Singapore. Lancet 356, 1338.
11 Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pullansch MA, Suleiman AB et al. (2000) Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 31, 678–683.
12 Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR and Shih SR (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemiologic Working Group. N Engl J Med 341, 929–935.
13 Kurzynska-Kokorniak A, Jackowiak P, Figlerowicz M and Figlerowicz M (2009) Human- and virus-encoded microRNAs as potential targets of antiviral therapy. Mini Rev Med Chem 9, 927–937.
14 Grey F, Tirabassi R, Meyers H, Wu G, McWeeney S, Hook L and Nelson JA (2010) A viral microRNA down-regulates multiple cell cycle genes through mRNA 5’UTRs. PLoS Pathog 6, e1000967.
15 Motsch N, Pfuhl T, Mrazek J, Barth S and Grasser FA (2007) Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol 4, 131–137.
16 Ahluwalia JK, Khan SZ, Soni K, Rawat P, Gupta A, Harhiran M, Scaria V, Lalwani M, Pillai B, Mitra D et al. (2008) Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology 5, 117.
17 Barth S, Pfuhl T, Mamiani A, Ehres C, Roemer K, Kremmer E, Jäger C, Hock J, Meister G and Grasser FA (2008) Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BalF5. Nucleic Acids Res 36, 666–675.
18 Lung RW-M, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL, Chan AW, Ng EK, Lo KW and To KF (2009). Modulation of LMP2A expression by a newly identified Epstein-Barr Virus-Encoded MicroRNA miR-BART22. Neoplasia 11, 1174-IN17.
19 Pastorino B, Noguierede A, Wurtz N, Gould E and de Lamballerie X (2010) Role of host cell factors in flavivirus infection: implications for pathogenesis and development of antiviral drugs. Antiviral Res 87, 281–294.
20 Jheng JR, Ho JY and Horng JT (2014) ER stress, autophagy, and RNA viruses. Front Microbiol 5, 388.
21 Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T and Koike S (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15, 798–801.
22 Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T and Shimizu H (2009) Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15, 794–797.
23 Yamayoshi S, Izuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T et al. (2012) Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol 86, 5686–5696.
24 Yamayoshi S, Ohka S, Fuji K and Koike S (2013) Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 87, 3335–3347.
25 Laszik Z, Jansen PJ, Cummings RD, Tedder TF, McEver RP and Moore KL (1996) PSGL-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic
lineage and in some nonhematopoietic cells. *Blood* **88**, 3010–3021.

26 Somers WS, Tang J, Shaw GD and Camphausen RT (2000) Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of p-and e-selectin bound to SEL6 and PSGL-1. *Cell* **103**, 467–479.

27 Ku Z, Ye X, Shi J, Wang X, Liu Q, Huang Z and López S (2015) Single neutralizing monoclonal antibodies targeting the VPI GH loop of enterovirus 71 inhibit both virus attachment and internalization during viral entry. *J Virol* **89**, 12084–12095.

28 He Y, Ong KC, Gao Z, Zhao X, Anderson VM, McNutt MA, Wong KT and Lu M (2014) Tonsillar crypt epithelium is an important extra-central nervous system site for viral replication in EV71 encephalomyelitis. *Am J Pathol* **184**, 714–720.

29 Siebert M, Westbroek W, Chen YC, Moaven N, Li Y, Velayati A, Saraiva-Pereira ML, Martin SE and Sidransky E (2014) Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells. *RNA Biol* **11**, 1291–1300.

30 Meeky RY, El-Ekiaby NM, Hamza MT, Elemam NM, El-Sayed M, Esmat G and Abdelaziz AI (2015) Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor. *J Infect* **70**, 78–87.

31 Sun JZ, Wang J, Wang S, Yuan D, Li Z, Yi B, Hou Q, Mao Y and Liu W (2014) MicroRNA miR-320a and miR-140 inhibit mink enteritis virus infection by repression of its receptor, feline transferrin receptor. *Virol J* **11**, 210.

32 Du J, Guo X, Gao S, Luo J, Gong X, Hao C, Yang B, Lin T, Shao J, Cong G et al. (2014) Induction of protection against foot-and-mouth disease virus in cell culture and transgenic suckling mice by miRNA targeting integrin alphav protein. *J Biotechnol* **187**, 154–161.

33 Ouda R, Onomoto K, Takahasi K, Edwards MR, Kato H, Yoneyama M and Fujita T (2011) Retinoic acid-inducible gene I-inducible miR-23b inhibits infections by minor group rhinoviruses through down-regulation of the very low density lipoprotein receptor. *J Biol Chem* **286**, 26210–26219.

34 Lin YW, Lin HY, Tsou YL, Chiara E, Hsiao KN, Shao HY, Liu CC, Sia C, Chong P and Chow YH (2012) Human SCARB2-mediated entry and endocytosis of EV71. *PLoS One* **7**, e30507.

35 Yamayoshi S, Fujii K and Koike S (2014) Receptors for enterovirus 71. *Emerg Microbes Infect* **3**, e53.

36 Hussain KM, Leong KL, Ng MM and Chu JJ (2011) The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71. *J Biol Chem* **286**, 309–321.

37 Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschi T, Manoharan M and Stoffel M (2005) Silencing of microRNAs in vivo with ‘antagonirs’. *Nature* **438**, 685–689.

38 Jopling CL, Yi M, Lancaster AM, Lemon SM and Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. *Science* **309**, 1577–1581.

39 Zheng Z, Ke X, Wang M, He S, Li Q, Zheng C, Zhang Z, Liu Y and Wang H (2013) Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome. *J Virol* **87**, 5645–5656.

40 Chen Y, Shen A, Rider PJ, Yu Y, Wu K, Mu Y, Hao Q, Liu Y, Gong H, Zhu Y et al. (2011) A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. *FASEB J* **25**, 4511–4521.

41 Yamayoshi S and Koike S (2011) Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection. *J Virol* **85**, 4937–4946.

42 Fu YR, Liu XJ, Li XJ, Shen ZZ, Yang B, Wu CC, Li JF, Miao LF, Ye HQ, Qiao GH et al. (2015) MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a. *J Virol* **89**, 1070–1082.

43 Zhao L, Zhu J, Zhou H, Zhao Z, Zou Z, Liu X, Lin X, Zhang X, Deng X, Wang R et al. (2015) Identification of cellular microRNA-136 as a dual regulator of RIG-I-mediated innate immunity that antagonizes H5N1 IAV replication in A549 cells. *Sci Rep* **5**, 14991.

44 Jopling CL, Norman KL and Sarnow P (2006) Positive and negative regulation of viral and cellular miRNAs by liver-specific microRNA miR-122. *Cold Spring Harb Symp Quant Biol* **71**, 369–376.

45 Wen BP, Dai HJ, Yang YH, Zhuang Y and Sheng R (2013) MicroRNA-23b inhibits enterovirus 71 replication through downregulation of EV71 VPl protein. *Intervirology* **56**, 195–200.

46 Fu Y, Xu W, Chen D, Feng C, Zhang L, Wang X, Lv X, Zheng N, Jin Y and Wu Z (2015) Enterovirus 71 induces autophagy by regulating has-miR-30a expression to promote viral replication. *Antiviral Res* **124**, 43–53.

47 Davidson BL and McCray PB Jr (2011) Current prospects for RNA interference-based therapies. *Nat Rev Genet* **12**, 329–340.

48 Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A et al. (2010) Postexposure protection of nonhuman primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. *Lancet* **375**, 1896–1905.

49 Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng BJ, Woodle MC et al. (2005) Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. *Nat Med* **11**, 944–951.